ArticlePLOS global public health2026
Expert consensus on pre-eclampsia risk screening tools for low- and middle-income countries: Development of a new Target Product Profile.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Risk screening tools can identify women at high-risk for developing pre-eclampsia, allowing for timely preventative care and monitoring. However, tools that are accurate, feasible and affordable for limited-resource settings are lacking. Target Product Profiles (TPPs) define the minimum and optimal criteria required for new products to achieve a specific health need. Through the Accelerating Innovation for Mothers (AIM) project, we developed the first TPP for pre-eclampsia risk screening tools, suitable for use in low- and middle-income countries (LMICs). We used a mixed-methods approach, including stakeholder interviews, an online multilingual survey, and public consultation to inform the draft TPP. Diverse stakeholders (e.g., clinicians, manufacturers, researchers) representing all WHO geographical regions were invited to participate. We used descriptive statistics to identify variables that met consensus (≥75% agree or strongly agree) from surveys and qualitative content analysis to identify emerging themes from interviews. We conducted 26 interviews and received 84 survey responses, from diverse participants in terms of geographies, gender and country income level. Consensus was reached on all but two of the 25 TPP variables (tool recommendations, sample collection). Following interview feedback, we modified the TPP to include three distinct sections (biophysical, biochemical and digital), allowing these tool types to be clearly defined. This is the first TPP on risk screening tools for predicting pre-eclampsia. This will facilitate the development, evaluation and advancement of pre-eclampsia risk screening tools for pregnant women. It can help ensure these tools address real-world needs and current gaps in pre-eclampsia related care in LMICs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.